Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
When should triptans be taken during a migraine attack?
Autore:
Schoenen, J;
Indirizzi:
Univ Liege, CHR Citadelle, Dept Neurol, B-4000 Liege, Belgium Univ Liege Liege Belgium B-4000 elle, Dept Neurol, B-4000 Liege, Belgium Univ Liege, CHR Citadelle, Dept Neuroanat, B-4000 Liege, Belgium Univ Liege Liege Belgium B-4000 e, Dept Neuroanat, B-4000 Liege, Belgium
Titolo Testata:
CNS DRUGS
fascicolo: 8, volume: 15, anno: 2001,
pagine: 583 - 587
SICI:
1172-7047(2001)15:8<583:WSTBTD>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
CUTANEOUS ALLODYNIA; CLINICAL-TRIALS; SUMATRIPTAN; HEADACHE; EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Schoenen, J Univ Liege, CHR Citadelle, Dept Neurol, Bld 12eme Ligne 1, B-4000 Liege, Belgium Univ Liege Bld 12eme Ligne 1 Liege Belgium B-4000 ge, Belgium
Citazione:
J. Schoenen, "When should triptans be taken during a migraine attack?", CNS DRUGS, 15(8), 2001, pp. 583-587

Abstract

The common strategy to treat a migraine attack as soon as it begins, made for classical acute antimigraine treatments such as ergotamine and analgesics, has not been transposed to the triptans. The recommendation to delay triptan intake until headache intensity is at least moderate is merely a habit generated by the protocol used in triptan trials and a nonvalidated attempt to reduce costs. It is also favoured by the few studies suggesting that sumatriptan is less effective when given early in an attack, especially during the aura phase. Recent retrospective analyses of small numbers of 'protocol violators in controlled trials of sumatriptan suggest that the drug ismore efficient when taken while the headache is mild. Pain-free responses and therapeutic gains over aspirin (acetylsalicylic acid)-metoclopramide orergotamine-caffeine combinations were increased under these conditions. The available circumstantial evidence is reviewed and discussed. Before any conclusion can be drawn and recommendation made, results are awaited from randomised controlled trials specifically addressing whether or not triptans are more efficient in mild headache. Meanwhile, there seems to be no medical reason to withhold treatment of a mild headache with a triptan as long astriptan intake does not exceed 1 or 2 doses per week. Most mild headaches in patients with migraine appear indeed to be mild migraine attacks, even when the headache characteristics are those of tension-type headache.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 23:57:16